WO2003024482A1 - Crustaceans as production systems for therapeutic proteins - Google Patents
Crustaceans as production systems for therapeutic proteins Download PDFInfo
- Publication number
- WO2003024482A1 WO2003024482A1 PCT/US2002/029081 US0229081W WO03024482A1 WO 2003024482 A1 WO2003024482 A1 WO 2003024482A1 US 0229081 W US0229081 W US 0229081W WO 03024482 A1 WO03024482 A1 WO 03024482A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic protein
- protein
- virus
- proteins
- therapeutic
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 101
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 83
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 52
- 241000238424 Crustacea Species 0.000 title claims abstract description 43
- 238000004519 manufacturing process Methods 0.000 title abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 8
- 241000700605 Viruses Species 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 30
- 241000238557 Decapoda Species 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 20
- 241000282414 Homo sapiens Species 0.000 claims description 19
- 230000014509 gene expression Effects 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 12
- 241000251468 Actinopterygii Species 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 244000144974 aquaculture Species 0.000 claims description 8
- 238000009360 aquaculture Methods 0.000 claims description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 241000282412 Homo Species 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 235000015170 shellfish Nutrition 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 241000607598 Vibrio Species 0.000 claims 2
- -1 antibodies Proteins 0.000 claims 2
- 210000004748 cultured cell Anatomy 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 claims 1
- 108020005202 Viral DNA Proteins 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 239000002028 Biomass Substances 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 241000238582 Artemia Species 0.000 description 21
- 241000701447 unidentified baculovirus Species 0.000 description 21
- 239000008188 pellet Substances 0.000 description 15
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 14
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 14
- 239000005090 green fluorescent protein Substances 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 13
- 241000238631 Hexapoda Species 0.000 description 11
- 235000019688 fish Nutrition 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000002955 isolation Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108090000565 Capsid Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 230000001418 larval effect Effects 0.000 description 4
- 230000000737 periodic effect Effects 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 241000238426 Anostraca Species 0.000 description 3
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 3
- 230000000366 juvenile effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 101800000263 Acidic protein Proteins 0.000 description 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 2
- 108050004290 Cecropin Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 241000710921 Infectious pancreatic necrosis virus Species 0.000 description 2
- 206010061217 Infestation Diseases 0.000 description 2
- 241000238553 Litopenaeus vannamei Species 0.000 description 2
- 206010048685 Oral infection Diseases 0.000 description 2
- 241000927735 Penaeus Species 0.000 description 2
- 241000700141 Rotifera Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000000514 hepatopancreas Anatomy 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000243290 Aequorea Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000239202 Chelicerata Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000723873 Tobacco mosaic virus Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000019553 satiation Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
- A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
- A01K67/0337—Genetically modified Arthropods
- A01K67/0338—Genetically modified Crustaceans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Definitions
- Such products may be of
- plants by direct modification of the plant's genome so that it produces a protein that a plant may never have produced before. Such plants are referred to as genetically
- GMO's modified organisms
- the plant e.g.
- Tobacco is infected with a virus (e.g. tobacco mosaic virus; TMN) which canies the gene for the human therapeutic protein.
- TMN tobacco mosaic virus
- the expression of the plant is modified without directly changing the plant's DNA.
- the human therapeutic protein is then isolated, purified and used for human therapeutic purposes.
- Recombinant microbes including bacteria, yeast and fungi have been used to produce human therapeutic proteins.
- recombinant microbes generally do not produce exact mimics of such proteins that are made in mammalian cells due to changes in post-translational modifications.
- recombinant microbes have not been used for agricultural purposes incorporating ingestion of the whole organism. In both the plant and microbial cases, the recombinant organism has simply been used as a factory, and the therapeutic protein is then isolated and purified prior to use.
- Certain recombinant proteins have been produced in insect cells using an insect virus expression system (Baculovirus). Such proteins are also produced in intact insect larvae following infection with modified Baculoviruses. In both cases, the insect cells or larvae are used as factories to produce the protein of interest, and the recombinant protein is then purified for pharmaceutical purposes. Proteins produced by insect cells are generally closer mimics to those produced in mammalian cells due to a closer approximation of post-translational modifications and the process is generally much less costly than the production in mammalian cells. However, the proteins produced by insect cells or insect larvae still require many steps of purification before they can be used therapeutically.
- Baculovirus insect virus expression system
- Certain crustaceans e.g., brine shrimp
- various aquaculture crops e.g., fish or shrimp
- the Artemia is "loaded” with certain microalgae, which
- certain beneficial nutrients can be provided from the algae to the larvae through the
- composition of matter which is an animal feed or feed component comprising a therapeutic protein or
- this invention provides a feed comprising a
- crustacean e.g. artemia
- a recombinant virus e.g., Baculovirus
- a protein of therapeutic value e.g., an antibody, or a protein that will convey an immunological response, or an antimicrobial capability.
- a feed could provide an oral vaccination for the consuming species.
- the artemia are used as a low-
- protein may be consumable by human or other animals as part of the whole artemia
- biomass or, alternatively, the protein can be extracted and purified to be provided as a
- the marine environment is filled with bacteria and viruses that can
- This invention provides a solution to this problem by providing a nutritional control method using the target animal's feed as the vector to deliver antiviral antibodies or fragments thereof, directly to the shrimp.
- These "Designer feeds” would deliver a therapeutic dose of antibody directly to the gut of the shrimp.
- This approach is known as "passive immunity” because the antibody remains outside the host organism and simply prevents viral infestation through the gut wall.
- the invention envisions the use of transgenic multicellular organisms (plants, animals, insects, etc) to deliver the antibody to the gut of the target animal through the consumption of the transgenic multicellular organism.
- the feed source itself may be infected with a host-specific virus that is engineered to produce the antibody, or fragment thereof, of interest in a multicellular organism that can be fed to the target animal.
- the feed material may deliver a portion of the virus (e.g. a coat protein) or fragment thereof in order to actively immunize the shrimp, other shellfish or fmfish or terrestrial animal that consumes the feed.
- Figure 1 represents a Pacific white shrimp (Penaeus vanname ⁇ ) that
- GFP as a fusion protein.
- Crustaceans are common elements in the food chain for either aquatic species or terrestrial species (including Aquaculture or Agriculture).
- One of the major problems with bacterial production of human proteins is that the microbially produced recombinant proteins are ineffective because of
- Antibodies or antibody fragments to desired targets such as White
- Spot virus or Taura virus may be prepared by routine immunization and selection of
- bactericidal and bacteriostatic peptides which will inhibit microbial growth and include, but are not limited to cecropins, peneadins, bactenecins, callinectins, myticins, tachyplesins, clavanins, misgurins, pleurocidins, parasins, histones, acidic proteins, and lysozymes.
- these peptides may be made in a crustacean host using recombinant methods well known to those in the art, and optionally provided as a feed component to convey resistance or tolerance to infestation.
- Crustaceans are the foodstuffs for many aquaculture species, and this invention contemplates recombinant production of therapeutic proteins in the natural or farm diet of juvenile fish (e.g., half-grown catfish) as well as fish larva.
- juvenile fish e.g., half-grown catfish
- fish larva e.g., half-grown catfish
- host organisms that make up part of the food chain for the feeding of larvae, juveniles and adults in aquaculture, as well as the same life sequence in the terrestrial animal feeds (e.g. pigs, chickens, and cows).
- Edible materials can be any materials that are ingested.
- One embodiment of this invention would be where crustaceans are genetically modified to produce the exogenous peptide and/or antibody or antibody fragments directly, and modified crustaceans are ingested.
- Post-harvest processing of some sort may be required to prepare the material for use.
- This invention contemplates normal (known) processes for converting the crustacean material into feeds. Such normal process include homogenization followed by extrusion into pellets of various sizes depending on the application (e.g., larval, juvenile or adult). Other modes of preparation would include spray drying, fluid bed drying, or even providing the material as a liquid suspension.
- crustaceans which express therapeutic proteins may be grown and harvested, followed by isolation of a fraction containing the therapeutic protein from the crustacean.
- additional processing steps may be applied to further purify the therapeutic protein as is known in the art.
- Example 1 Production of viral antigen in artemia.
- Infectious pancreatic necrosis virus (IPNN) is an example of a virus that can cause a high mortality in juvenile trout and salmon. In these animals, it is best to vaccinate as early as possible. Thus, it may be beneficial to deliver an oral vaccine at an early larval stage.
- the IP ⁇ V genome contains two segments; the larger segment contains the genes for the NP2, NP3 and NP4 viral coat proteins.
- a full length cD ⁇ A clone containing one or more of the viral coat protein genes, and a transfection marker (e.g., Green Fluorescent Protein - GFP), is prepared using conventional molecular biology techniques.
- This fragment is then ligated into a Baculovirus transformation vector, such as pAcUW21, at the cloning site behind the PI 0 promotor region.
- Baculovirus transformation vector such as pAcUW21
- the recombinant Baculovirus containing both the viral coat protein gene and the GFP gene, is then used to fransfect artemia.
- the infection and expression of the product of interest e.g., NP2
- the artemia can be harvested and fed to the fish larvae. Ingestion of the NP2-expressing artemia by fish larvae will provide a mode of oral vaccination that is both inexpensive and effective.
- WSN White Spot Virus
- Fabs antibody fragments
- E. coli E. coli
- the genes for these Fabs can be prepared and isolated by technology known to those of skill in the art. The gene will then be spliced into a Baculovirus vector and used to infect the artemia.
- E. coli is then transformed and the recombinant phage library is rescued and triple panned to select the antigen- positive recombinant phage antibodies.
- the ScFv gene coding for a Fab of highest specificity, is then isolated from the plasmid and ligated into a Baculovirus expression system.
- a Baculovirus expression system may also contain an expression marker for transfection such as green fluorescent protein (GFP).
- GFP green fluorescent protein
- Artemia can then be infected with the Baculovirus, and the extent of infectivity can be easily monitored by the intensity of the green color. In such a case, the infected shrimp will also produce an antibody against WSN.
- biomass as a feed additive will introduce the antibody or antibody fragment directly into the animal, thus providing passive immunity.
- Example 3 Expression of a bactericidal or bacteriostatic protein in artemia.
- a bactericidal or bacteriostatic protein is chosen for the particular application. Suitable examples include proteins of the penaeidin class for pathogenic control in shrimp. Penaeldins are members of a family of antimicrobial peptides isolated from crustaceans (e.g., Penaeus shrimp).
- Antimicrobial peptides may also come from insects and chelicerates and may include but are not limited to cecropins, peneadins, bactenecins, callinectins, myticins, tachyplesins, clavanins, misgurins, pleurocidins, parasins, histones, acidic proteins, and lysozymes.
- the gene for the chosen protein or peptide is either isolated from the original source, or an amplification source, or it can be made synthetically. The gene is spliced into a bacculorviras vector which may also contain the gene for Green Fluorescent Protein (GFP).
- GFP Green Fluorescent Protein
- the virus is then used to tranfect artemia and the production of the bacteriostatic or bacteriocidal protein is monitored by the intensity of expression of GFP.
- the artemia are added to the diet of the fish or shrimp.
- the bateriostatic or bacteriocidal proteins are delivered directly to the gut of the animal in the form of the artemia itself.
- the entire artemia can be used as a feed or feed component.
- the crustacean may be homogenized and extruded into pellets suitable for feed applications.
- the Baculovirus vectors can be inactivated by high temperature or other procedures familiar to those experts in the field prior to use as feeds. [023] Example 4. Expression of Human Insulin in Artemia.
- Human insulin is a human therapeutic protein that may be produced in crustaceans.
- the gene for human insulin (or any other human therapeutic protein) is obtained, or synthetically produced, and ligated into a Baculovirus expression vector.
- the Baculovirus expression vector may also contain a transfection marker such as Green (or Red) Fluorescent Protein (GFP or R-FP).
- GFP or R-FP Green Fluorescent Protein
- the Baculovirus is then used to infect a culture of a crustacean such as artemia.
- the level of expression of the therapeutic protein will be determined by the intensity of the fluorescence caused by the GFP or RFP.
- the crustaceans are harvested.
- Brine shrimp may be used directly as a wet paste, or dried by some appropriate process (e.g.
- brine shrimp may be broken and the protein of interest isolated and purified by conventional biochemical methodologies.
- the purified protein may be used in an oral, nasal, dermal or injectable delivery form.
- Example 5 Production from Other Crustaceans and Rotifers.
- other crustaceans e.g., crab, crawfish, lobster, etc
- Such an infection might occur at a much later stage in the life cycle, such that the fully mature crustacean may carry the pharmaceutical product in a much more food acceptable form.
- certain other crustaceans e.g., crab, crawfish
- rotifers may be used as a vector for delivery of the therapeutic proteins following the procedures in examples 1- 4.
- Baculovirus Expression system (Invitrogen) was utilized for cloning and transfection.
- a 720 kb fragment containing GFP was fused to the polyhedron (pPolh) promoter and
- sucrose-purified virus pellet was maintained at
- one-gram shrimp were placed in each container and allowed to acclimatize overnight.
- a pellet matrix was prepared by first adding 100 mg of alginic
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Animal Husbandry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Virology (AREA)
- Feed For Specific Animals (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Fodder In General (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002460558A CA2460558A1 (en) | 2001-09-14 | 2002-09-13 | Crustaceans as production systems for therapeutic proteins |
JP2003528576A JP4472336B2 (en) | 2001-09-14 | 2002-09-13 | Crustaceans as production systems for therapeutic proteins |
EP02775802A EP1436004A1 (en) | 2001-09-14 | 2002-09-13 | Crustaceans as production systems for therapeutic proteins |
US10/778,175 US7550647B2 (en) | 2001-09-14 | 2004-02-17 | Transfected shrimp as production systems for therapeutic proteins |
US12/489,905 US7932056B2 (en) | 2001-09-14 | 2009-06-23 | Crustaceans as production systems for therapeutic proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31886701P | 2001-09-14 | 2001-09-14 | |
US60/318,867 | 2001-09-14 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/778,175 Continuation-In-Part US7550647B2 (en) | 2001-09-14 | 2004-02-17 | Transfected shrimp as production systems for therapeutic proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003024482A1 true WO2003024482A1 (en) | 2003-03-27 |
WO2003024482B1 WO2003024482B1 (en) | 2003-11-27 |
Family
ID=23239884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/029081 WO2003024482A1 (en) | 2001-09-14 | 2002-09-13 | Crustaceans as production systems for therapeutic proteins |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1436004A1 (en) |
JP (1) | JP4472336B2 (en) |
CA (1) | CA2460558A1 (en) |
WO (1) | WO2003024482A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004024862A2 (en) * | 2002-09-13 | 2004-03-25 | Wockhardt Limited | Yeast protein expression secretion system |
US7550647B2 (en) | 2001-09-14 | 2009-06-23 | Advanced Bionutrition | Transfected shrimp as production systems for therapeutic proteins |
CN102742544A (en) * | 2011-04-20 | 2012-10-24 | 董锦铭 | Low-carbon environment-friendly micro-ecological fermentation bed pig farming technology |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4141986A (en) * | 1976-04-28 | 1979-02-27 | Merck & Co., Inc. | Antibiotics 890A2 and 890A5 |
US5202422A (en) * | 1989-10-27 | 1993-04-13 | The Scripps Research Institute | Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use |
US5681746A (en) * | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
US5863775A (en) * | 1994-02-28 | 1999-01-26 | The University Of Leeds | Control of parasites |
WO2000075288A1 (en) * | 1999-06-04 | 2000-12-14 | The Regents Of The University Of California | Transgenic decapods, decapod cell lines and methods of producing same |
US20010006953A1 (en) * | 1998-07-06 | 2001-07-05 | Steven E. Poet | Delivery of nucleic acid into aquatic animals |
-
2002
- 2002-09-13 WO PCT/US2002/029081 patent/WO2003024482A1/en active Application Filing
- 2002-09-13 JP JP2003528576A patent/JP4472336B2/en not_active Expired - Fee Related
- 2002-09-13 CA CA002460558A patent/CA2460558A1/en not_active Abandoned
- 2002-09-13 EP EP02775802A patent/EP1436004A1/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4141986A (en) * | 1976-04-28 | 1979-02-27 | Merck & Co., Inc. | Antibiotics 890A2 and 890A5 |
US5202422A (en) * | 1989-10-27 | 1993-04-13 | The Scripps Research Institute | Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use |
US5863775A (en) * | 1994-02-28 | 1999-01-26 | The University Of Leeds | Control of parasites |
US5681746A (en) * | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
US20010006953A1 (en) * | 1998-07-06 | 2001-07-05 | Steven E. Poet | Delivery of nucleic acid into aquatic animals |
WO2000075288A1 (en) * | 1999-06-04 | 2000-12-14 | The Regents Of The University Of California | Transgenic decapods, decapod cell lines and methods of producing same |
Non-Patent Citations (3)
Title |
---|
MASON H.S. ET AL.: "Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice", PROC. NATL. ACAD. SCI. USA, vol. 93, May 1996 (1996-05-01), pages 5335 - 5340, XP002025358 * |
MODELSKA A. ET AL.: "Immunization against rabies with plant derived antigen", PROC. NATL. ACAD. SCI. USA, vol. 95, March 1998 (1998-03-01), pages 2481 - 2485, XP002921640 * |
YU J.: "A plant based multicomponent vaccine protects mice from enteric diseases", NATURE BIOTECH., vol. 19, June 2001 (2001-06-01), pages 548 - 552, XP002959140 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7550647B2 (en) | 2001-09-14 | 2009-06-23 | Advanced Bionutrition | Transfected shrimp as production systems for therapeutic proteins |
WO2004024862A2 (en) * | 2002-09-13 | 2004-03-25 | Wockhardt Limited | Yeast protein expression secretion system |
WO2004024862A3 (en) * | 2002-09-13 | 2006-07-20 | Wockhardt Ltd | Yeast protein expression secretion system |
CN102742544A (en) * | 2011-04-20 | 2012-10-24 | 董锦铭 | Low-carbon environment-friendly micro-ecological fermentation bed pig farming technology |
Also Published As
Publication number | Publication date |
---|---|
WO2003024482B1 (en) | 2003-11-27 |
JP2005508627A (en) | 2005-04-07 |
CA2460558A1 (en) | 2003-03-27 |
EP1436004A1 (en) | 2004-07-14 |
JP4472336B2 (en) | 2010-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1429623B1 (en) | Delivery of disease control in aquaculture and agriculture using nutritional feeds containing bioactive proteins produced by viruses | |
US8198067B2 (en) | Delivery of disease control in aquaculture and agriculture using microbes containing bioactive proteins | |
US7932056B2 (en) | Crustaceans as production systems for therapeutic proteins | |
US20110158946A1 (en) | Methods and Compositions for control of disease in aquaculture | |
AU2002255851A1 (en) | Microbial feeds for aquaculture and agriculture | |
CA2935635C (en) | Algal based edible vaccines | |
EP1420819B1 (en) | Sub-unit vaccine for infectious pancreatic necrosis virus | |
WO2003087812A1 (en) | Enclosed aquacultural systems for production of purified recombinant proteins | |
US20070248742A1 (en) | Transgenic aquatic invertebrates as a bioreactor for production of recombinant polypeptides | |
JP4472336B2 (en) | Crustaceans as production systems for therapeutic proteins | |
Peng et al. | Construction of an easily detectable transgenic Synechococcus elongatus PCC 7942 against White Spot Syndrome Virus using vp 28 and mOrange Gene and its metabolism in shrimp | |
AU2004240233A1 (en) | Compositions for reducing virus infection rate in aquatic crustaceans and applications thereof | |
Chen et al. | Biotechnological application of transgenic fish technology in aquaculture | |
CN1171813A (en) | Delivery system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
B | Later publication of amended claims |
Free format text: 20030327 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10778175 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003528576 Country of ref document: JP Ref document number: 2460558 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 797/DELNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002775802 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002775802 Country of ref document: EP |